Crystal Rock Capital Management trimmed its holdings in shares of Allergan plc (NYSE:AGN) by 7.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 19,461 shares of the company’s stock after selling 1,470 shares during the period. Allergan comprises approximately 2.1% of Crystal Rock Capital Management’s portfolio, making the stock its 19th largest position. Crystal Rock Capital Management’s holdings in Allergan were worth $3,183,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Peloton Wealth Strategists boosted its position in Allergan by 37.1% during the third quarter. Peloton Wealth Strategists now owns 10,485 shares of the company’s stock valued at $2,149,000 after buying an additional 2,835 shares during the period. Coronation Fund Managers Ltd. boosted its position in Allergan by 35.9% during the fourth quarter. Coronation Fund Managers Ltd. now owns 203,238 shares of the company’s stock valued at $33,246,000 after buying an additional 53,653 shares during the period. Bronfman E.L. Rothschild L.P. boosted its position in Allergan by 16.1% during the third quarter. Bronfman E.L. Rothschild L.P. now owns 5,177 shares of the company’s stock valued at $1,061,000 after buying an additional 718 shares during the period. Prudential Financial Inc. boosted its position in Allergan by 1.1% during the third quarter. Prudential Financial Inc. now owns 1,366,552 shares of the company’s stock valued at $280,075,000 after buying an additional 14,440 shares during the period. Finally, CNA Financial Corp purchased a new stake in Allergan during the third quarter valued at about $2,597,000. Institutional investors and hedge funds own 79.66% of the company’s stock.
In related news, CFO Matthew M. Walsh acquired 2,000 shares of the stock in a transaction on Wednesday, February 21st. The stock was acquired at an average cost of $160.94 per share, for a total transaction of $321,880.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider William Meury sold 58,879 shares of the firm’s stock in a transaction dated Wednesday, February 14th. The stock was sold at an average price of $160.62, for a total transaction of $9,457,144.98. The disclosure for this sale can be found here. Insiders acquired 19,630 shares of company stock valued at $3,211,937 over the last 90 days. 0.36% of the stock is currently owned by company insiders.
Shares of Allergan plc (NYSE:AGN) opened at $165.76 on Tuesday. The company has a quick ratio of 1.06, a current ratio of 1.16 and a debt-to-equity ratio of 0.38. Allergan plc has a 1-year low of $156.00 and a 1-year high of $256.80. The company has a market cap of $53,541.63, a PE ratio of -12.35, a price-to-earnings-growth ratio of 1.15 and a beta of 1.19.
Allergan (NYSE:AGN) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $4.86 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $4.74 by $0.12. Allergan had a negative net margin of 26.32% and a positive return on equity of 8.43%. The business had revenue of $4.33 billion during the quarter, compared to analyst estimates of $4.28 billion. During the same period last year, the business posted $3.90 earnings per share. Allergan’s quarterly revenue was up 12.0% compared to the same quarter last year. equities analysts anticipate that Allergan plc will post 15.58 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 28th. Shareholders of record on Wednesday, February 28th will be issued a $0.72 dividend. The ex-dividend date is Tuesday, February 27th. This is a positive change from Allergan’s previous quarterly dividend of $0.70. This represents a $2.88 annualized dividend and a yield of 1.74%. Allergan’s dividend payout ratio (DPR) is -20.86%.
WARNING: “Crystal Rock Capital Management Has $3.18 Million Holdings in Allergan plc (AGN)” was reported by Ticker Report and is owned by of Ticker Report. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3226128/crystal-rock-capital-management-has-3-18-million-holdings-in-allergan-plc-agn.html.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.